nodes	percent_of_prediction	percent_of_DWPC	metapath
Sparfloxacin—ABCC2—esophageal cancer	0.451	0.731	CbGaD
Sparfloxacin—ABCB1—esophageal cancer	0.166	0.269	CbGaD
Sparfloxacin—ABCC2—Carboplatin—esophageal cancer	0.097	0.349	CbGbCtD
Sparfloxacin—ABCC2—Cisplatin—esophageal cancer	0.0829	0.298	CbGbCtD
Sparfloxacin—ABCC2—Methotrexate—esophageal cancer	0.0538	0.193	CbGbCtD
Sparfloxacin—ABCB1—Cisplatin—esophageal cancer	0.027	0.0971	CbGbCtD
Sparfloxacin—ABCB1—Methotrexate—esophageal cancer	0.0175	0.063	CbGbCtD
Sparfloxacin—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00113	0.0431	CbGpPWpGaD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT14—esophageal cancer	0.00104	0.0393	CbGpPWpGaD
Sparfloxacin—ABCC2—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.000981	0.0372	CbGpPWpGaD
Sparfloxacin—Lomefloxacin—ABCC2—esophageal cancer	0.000902	0.404	CrCbGaD
Sparfloxacin—ABCB1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.000869	0.033	CbGpPWpGaD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—esophageal cancer	0.000845	0.032	CbGpPWpGaD
Sparfloxacin—Ofloxacin—ABCC2—esophageal cancer	0.000771	0.346	CrCbGaD
Sparfloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000652	0.0247	CbGpPWpGaD
Sparfloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000652	0.0247	CbGpPWpGaD
Sparfloxacin—Metrorrhagia—Capecitabine—esophageal cancer	0.000591	0.00779	CcSEcCtD
Sparfloxacin—Tongue disorder—Capecitabine—esophageal cancer	0.00058	0.00765	CcSEcCtD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—SFN—esophageal cancer	0.000576	0.0219	CbGpPWpGaD
Sparfloxacin—Hiccups—Cisplatin—esophageal cancer	0.000573	0.00755	CcSEcCtD
Sparfloxacin—Haemoptysis—Capecitabine—esophageal cancer	0.00057	0.00752	CcSEcCtD
Sparfloxacin—Herpes zoster—Capecitabine—esophageal cancer	0.000561	0.00739	CcSEcCtD
Sparfloxacin—Body temperature increased—Carboplatin—esophageal cancer	0.000551	0.00726	CcSEcCtD
Sparfloxacin—Otitis media—Capecitabine—esophageal cancer	0.000542	0.00715	CcSEcCtD
Sparfloxacin—Hyperaesthesia—Capecitabine—esophageal cancer	0.000538	0.00709	CcSEcCtD
Sparfloxacin—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000537	0.0204	CbGpPWpGaD
Sparfloxacin—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000534	0.0202	CbGpPWpGaD
Sparfloxacin—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000528	0.00696	CcSEcCtD
Sparfloxacin—Vaginal discharge—Methotrexate—esophageal cancer	0.000516	0.00681	CcSEcCtD
Sparfloxacin—Petechiae—Capecitabine—esophageal cancer	0.000513	0.00676	CcSEcCtD
Sparfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.000496	0.0188	CbGpPWpGaD
Sparfloxacin—Embolism—Methotrexate—esophageal cancer	0.000489	0.00645	CcSEcCtD
Sparfloxacin—ABCC2—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000487	0.0185	CbGpPWpGaD
Sparfloxacin—Aphasia—Methotrexate—esophageal cancer	0.000484	0.00639	CcSEcCtD
Sparfloxacin—ABCB1—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000476	0.018	CbGpPWpGaD
Sparfloxacin—Polyuria—Cisplatin—esophageal cancer	0.000473	0.00624	CcSEcCtD
Sparfloxacin—Skin discolouration—Capecitabine—esophageal cancer	0.000467	0.00616	CcSEcCtD
Sparfloxacin—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.000467	0.00616	CcSEcCtD
Sparfloxacin—Cellulitis—Capecitabine—esophageal cancer	0.000464	0.00612	CcSEcCtD
Sparfloxacin—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00046	0.00607	CcSEcCtD
Sparfloxacin—Herpes simplex—Capecitabine—esophageal cancer	0.000458	0.00604	CcSEcCtD
Sparfloxacin—Nocturia—Capecitabine—esophageal cancer	0.000455	0.006	CcSEcCtD
Sparfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.000453	0.0172	CbGpPWpGaD
Sparfloxacin—Renal failure acute—Cisplatin—esophageal cancer	0.00045	0.00594	CcSEcCtD
Sparfloxacin—Lung disorder—Methotrexate—esophageal cancer	0.000444	0.00585	CcSEcCtD
Sparfloxacin—Cyanosis—Methotrexate—esophageal cancer	0.000444	0.00585	CcSEcCtD
Sparfloxacin—Interstitial lung disease—Methotrexate—esophageal cancer	0.000444	0.00585	CcSEcCtD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—esophageal cancer	0.000444	0.0168	CbGpPWpGaD
Sparfloxacin—Amnesia—Cisplatin—esophageal cancer	0.000442	0.00583	CcSEcCtD
Sparfloxacin—Gait disturbance—Capecitabine—esophageal cancer	0.000432	0.0057	CcSEcCtD
Sparfloxacin—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000429	0.00566	CcSEcCtD
Sparfloxacin—Neck pain—Capecitabine—esophageal cancer	0.000427	0.00563	CcSEcCtD
Sparfloxacin—Hiccups—Capecitabine—esophageal cancer	0.000422	0.00556	CcSEcCtD
Sparfloxacin—Herpes zoster—Methotrexate—esophageal cancer	0.000417	0.0055	CcSEcCtD
Sparfloxacin—Candida infection—Capecitabine—esophageal cancer	0.000403	0.00531	CcSEcCtD
Sparfloxacin—Face oedema—Cisplatin—esophageal cancer	0.000401	0.00529	CcSEcCtD
Sparfloxacin—Gingivitis—Methotrexate—esophageal cancer	0.0004	0.00528	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000387	0.0147	CbGpPWpGaD
Sparfloxacin—Petechiae—Methotrexate—esophageal cancer	0.000382	0.00504	CcSEcCtD
Sparfloxacin—Mouth ulceration—Capecitabine—esophageal cancer	0.000382	0.00503	CcSEcCtD
Sparfloxacin—Ecchymosis—Capecitabine—esophageal cancer	0.000382	0.00503	CcSEcCtD
Sparfloxacin—Urine output increased—Capecitabine—esophageal cancer	0.000382	0.00503	CcSEcCtD
Sparfloxacin—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00038	0.005	CcSEcCtD
Sparfloxacin—TOP2A—Gastric Cancer Network 1—NOTCH1—esophageal cancer	0.000368	0.014	CbGpPWpGaD
Sparfloxacin—Mental disability—Capecitabine—esophageal cancer	0.000366	0.00483	CcSEcCtD
Sparfloxacin—Ear pain—Capecitabine—esophageal cancer	0.000359	0.00473	CcSEcCtD
Sparfloxacin—Sleep disorder—Capecitabine—esophageal cancer	0.000354	0.00467	CcSEcCtD
Sparfloxacin—Pancreatitis—Cisplatin—esophageal cancer	0.000352	0.00464	CcSEcCtD
Sparfloxacin—Polyuria—Capecitabine—esophageal cancer	0.000349	0.0046	CcSEcCtD
Sparfloxacin—Skin discolouration—Methotrexate—esophageal cancer	0.000348	0.00459	CcSEcCtD
Sparfloxacin—Gastroenteritis—Capecitabine—esophageal cancer	0.000346	0.00456	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000345	0.0131	CbGpPWpGaD
Sparfloxacin—Pancytopenia—Cisplatin—esophageal cancer	0.000341	0.0045	CcSEcCtD
Sparfloxacin—Herpes simplex—Methotrexate—esophageal cancer	0.000341	0.00449	CcSEcCtD
Sparfloxacin—Hepatic failure—Capecitabine—esophageal cancer	0.000341	0.00449	CcSEcCtD
Sparfloxacin—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000339	0.00447	CcSEcCtD
Sparfloxacin—Eye pain—Capecitabine—esophageal cancer	0.000339	0.00447	CcSEcCtD
Sparfloxacin—Renal failure acute—Capecitabine—esophageal cancer	0.000332	0.00438	CcSEcCtD
Sparfloxacin—Increased appetite—Capecitabine—esophageal cancer	0.000326	0.0043	CcSEcCtD
Sparfloxacin—Amnesia—Capecitabine—esophageal cancer	0.000326	0.0043	CcSEcCtD
Sparfloxacin—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000325	0.00428	CcSEcCtD
Sparfloxacin—TOP2A—Circadian rythm related genes—CRTC1—esophageal cancer	0.000324	0.0123	CbGpPWpGaD
Sparfloxacin—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000324	0.0123	CbGpPWpGaD
Sparfloxacin—Atrial fibrillation—Capecitabine—esophageal cancer	0.000323	0.00426	CcSEcCtD
Sparfloxacin—Thirst—Capecitabine—esophageal cancer	0.000322	0.00424	CcSEcCtD
Sparfloxacin—Vasculitis—Methotrexate—esophageal cancer	0.000322	0.00424	CcSEcCtD
Sparfloxacin—Dermatitis bullous—Capecitabine—esophageal cancer	0.000321	0.00423	CcSEcCtD
Sparfloxacin—Arthritis—Capecitabine—esophageal cancer	0.000315	0.00416	CcSEcCtD
Sparfloxacin—Vaginal inflammation—Methotrexate—esophageal cancer	0.000314	0.00414	CcSEcCtD
Sparfloxacin—Stomatitis—Cisplatin—esophageal cancer	0.000312	0.00412	CcSEcCtD
Sparfloxacin—Conjunctivitis—Cisplatin—esophageal cancer	0.000311	0.0041	CcSEcCtD
Sparfloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000308	0.0117	CbGpPWpGaD
Sparfloxacin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000306	0.0116	CbGpPWpGaD
Sparfloxacin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000306	0.0116	CbGpPWpGaD
Sparfloxacin—Osteoarthritis—Capecitabine—esophageal cancer	0.000306	0.00404	CcSEcCtD
Sparfloxacin—Diplopia—Capecitabine—esophageal cancer	0.000306	0.00404	CcSEcCtD
Sparfloxacin—Migraine—Capecitabine—esophageal cancer	0.000302	0.00398	CcSEcCtD
Sparfloxacin—Vaginal infection—Methotrexate—esophageal cancer	0.000297	0.00391	CcSEcCtD
Sparfloxacin—Face oedema—Capecitabine—esophageal cancer	0.000296	0.0039	CcSEcCtD
Sparfloxacin—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000294	0.0112	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000294	0.0111	CbGpPWpGaD
Sparfloxacin—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000293	0.0111	CbGpPWpGaD
Sparfloxacin—Urinary retention—Capecitabine—esophageal cancer	0.000291	0.00384	CcSEcCtD
Sparfloxacin—Mood swings—Capecitabine—esophageal cancer	0.00029	0.00383	CcSEcCtD
Sparfloxacin—Ataxia—Capecitabine—esophageal cancer	0.000288	0.0038	CcSEcCtD
Sparfloxacin—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000287	0.0109	CbGpPWpGaD
Sparfloxacin—Ecchymosis—Methotrexate—esophageal cancer	0.000284	0.00375	CcSEcCtD
Sparfloxacin—Mouth ulceration—Methotrexate—esophageal cancer	0.000284	0.00375	CcSEcCtD
Sparfloxacin—Urine output increased—Methotrexate—esophageal cancer	0.000284	0.00375	CcSEcCtD
Sparfloxacin—Levofloxacin—ABCB1—esophageal cancer	0.000284	0.127	CrCbGaD
Sparfloxacin—Dry skin—Capecitabine—esophageal cancer	0.000281	0.0037	CcSEcCtD
Sparfloxacin—Abdominal pain upper—Capecitabine—esophageal cancer	0.00028	0.00369	CcSEcCtD
Sparfloxacin—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00028	0.00369	CcSEcCtD
Sparfloxacin—Pulmonary oedema—Methotrexate—esophageal cancer	0.00028	0.00369	CcSEcCtD
Sparfloxacin—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000276	0.00364	CcSEcCtD
Sparfloxacin—Ciprofloxacin—ABCB1—esophageal cancer	0.000274	0.123	CrCbGaD
Sparfloxacin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000273	0.0104	CbGpPWpGaD
Sparfloxacin—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00027	0.00356	CcSEcCtD
Sparfloxacin—Tinnitus—Cisplatin—esophageal cancer	0.000268	0.00353	CcSEcCtD
Sparfloxacin—Lymphadenopathy—Methotrexate—esophageal cancer	0.000267	0.00352	CcSEcCtD
Sparfloxacin—Asthma—Capecitabine—esophageal cancer	0.000265	0.00349	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.000261	0.00991	CbGpPWpGaD
Sparfloxacin—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.000261	0.0099	CbGpPWpGaD
Sparfloxacin—Polyuria—Methotrexate—esophageal cancer	0.00026	0.00342	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000259	0.00983	CbGpPWpGaD
Sparfloxacin—Angina pectoris—Capecitabine—esophageal cancer	0.000258	0.0034	CcSEcCtD
Sparfloxacin—Arrhythmia—Cisplatin—esophageal cancer	0.000257	0.00339	CcSEcCtD
Sparfloxacin—Bronchitis—Capecitabine—esophageal cancer	0.000255	0.00336	CcSEcCtD
Sparfloxacin—Alopecia—Cisplatin—esophageal cancer	0.000254	0.00335	CcSEcCtD
Sparfloxacin—Hepatic failure—Methotrexate—esophageal cancer	0.000254	0.00335	CcSEcCtD
Sparfloxacin—Pancytopenia—Capecitabine—esophageal cancer	0.000251	0.00332	CcSEcCtD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—esophageal cancer	0.00025	0.0095	CbGpPWpGaD
Sparfloxacin—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000249	0.00945	CbGpPWpGaD
Sparfloxacin—Dysuria—Capecitabine—esophageal cancer	0.000248	0.00326	CcSEcCtD
Sparfloxacin—Renal failure acute—Methotrexate—esophageal cancer	0.000247	0.00326	CcSEcCtD
Sparfloxacin—Flatulence—Cisplatin—esophageal cancer	0.000247	0.00325	CcSEcCtD
Sparfloxacin—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000242	0.00319	CcSEcCtD
Sparfloxacin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000242	0.00319	CcSEcCtD
Sparfloxacin—Pneumonia—Capecitabine—esophageal cancer	0.000237	0.00313	CcSEcCtD
Sparfloxacin—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000236	0.00311	CcSEcCtD
Sparfloxacin—Tremor—Cisplatin—esophageal cancer	0.000235	0.00309	CcSEcCtD
Sparfloxacin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000234	0.00309	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000232	0.00306	CcSEcCtD
Sparfloxacin—Jaundice—Capecitabine—esophageal cancer	0.00023	0.00303	CcSEcCtD
Sparfloxacin—Stomatitis—Capecitabine—esophageal cancer	0.00023	0.00303	CcSEcCtD
Sparfloxacin—Conjunctivitis—Capecitabine—esophageal cancer	0.00023	0.00303	CcSEcCtD
Sparfloxacin—Urinary tract infection—Capecitabine—esophageal cancer	0.00023	0.00303	CcSEcCtD
Sparfloxacin—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000229	0.0087	CbGpPWpGaD
Sparfloxacin—Osteoarthritis—Methotrexate—esophageal cancer	0.000228	0.00301	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000228	0.00865	CbGpPWpGaD
Sparfloxacin—Malaise—Cisplatin—esophageal cancer	0.000226	0.00298	CcSEcCtD
Sparfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000225	0.00854	CbGpPWpGaD
Sparfloxacin—Haematuria—Capecitabine—esophageal cancer	0.000225	0.00297	CcSEcCtD
Sparfloxacin—Epistaxis—Capecitabine—esophageal cancer	0.000223	0.00294	CcSEcCtD
Sparfloxacin—Agranulocytosis—Capecitabine—esophageal cancer	0.00022	0.0029	CcSEcCtD
Sparfloxacin—Convulsion—Cisplatin—esophageal cancer	0.000217	0.00286	CcSEcCtD
Sparfloxacin—Mood swings—Methotrexate—esophageal cancer	0.000216	0.00285	CcSEcCtD
Sparfloxacin—Ataxia—Methotrexate—esophageal cancer	0.000214	0.00283	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000214	0.00813	CbGpPWpGaD
Sparfloxacin—Myalgia—Cisplatin—esophageal cancer	0.000213	0.00281	CcSEcCtD
Sparfloxacin—Haemoglobin—Capecitabine—esophageal cancer	0.000213	0.00281	CcSEcCtD
Sparfloxacin—Rhinitis—Capecitabine—esophageal cancer	0.000212	0.0028	CcSEcCtD
Sparfloxacin—Anxiety—Cisplatin—esophageal cancer	0.000212	0.0028	CcSEcCtD
Sparfloxacin—Hepatitis—Capecitabine—esophageal cancer	0.000212	0.00279	CcSEcCtD
Sparfloxacin—Haemorrhage—Capecitabine—esophageal cancer	0.000212	0.00279	CcSEcCtD
Sparfloxacin—Hypoaesthesia—Capecitabine—esophageal cancer	0.000211	0.00278	CcSEcCtD
Sparfloxacin—Discomfort—Cisplatin—esophageal cancer	0.000211	0.00278	CcSEcCtD
Sparfloxacin—Pharyngitis—Capecitabine—esophageal cancer	0.00021	0.00277	CcSEcCtD
Sparfloxacin—Oedema peripheral—Capecitabine—esophageal cancer	0.000209	0.00275	CcSEcCtD
Sparfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000206	0.00781	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.000206	0.0078	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.000206	0.0078	CbGpPWpGaD
Sparfloxacin—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000205	0.00271	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000204	0.00269	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.000203	0.00769	CbGpPWpGaD
Sparfloxacin—Erythema multiforme—Capecitabine—esophageal cancer	0.0002	0.00264	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Cisplatin—esophageal cancer	0.0002	0.00264	CcSEcCtD
Sparfloxacin—Tachycardia—Cisplatin—esophageal cancer	0.000199	0.00263	CcSEcCtD
Sparfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—esophageal cancer	0.000199	0.00754	CbGpPWpGaD
Sparfloxacin—Tinnitus—Capecitabine—esophageal cancer	0.000198	0.00261	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000197	0.0026	CcSEcCtD
Sparfloxacin—Asthma—Methotrexate—esophageal cancer	0.000197	0.0026	CcSEcCtD
Sparfloxacin—Anorexia—Cisplatin—esophageal cancer	0.000195	0.00257	CcSEcCtD
Sparfloxacin—Pancreatitis—Methotrexate—esophageal cancer	0.000193	0.00255	CcSEcCtD
Sparfloxacin—Chills—Capecitabine—esophageal cancer	0.00019	0.00251	CcSEcCtD
Sparfloxacin—Arrhythmia—Capecitabine—esophageal cancer	0.000189	0.0025	CcSEcCtD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—MYC—esophageal cancer	0.000188	0.00713	CbGpPWpGaD
Sparfloxacin—Alopecia—Capecitabine—esophageal cancer	0.000187	0.00247	CcSEcCtD
Sparfloxacin—Pancytopenia—Methotrexate—esophageal cancer	0.000187	0.00247	CcSEcCtD
Sparfloxacin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000186	0.00245	CcSEcCtD
Sparfloxacin—Dysuria—Methotrexate—esophageal cancer	0.000184	0.00243	CcSEcCtD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—EGFR—esophageal cancer	0.000184	0.00698	CbGpPWpGaD
Sparfloxacin—Paraesthesia—Cisplatin—esophageal cancer	0.000183	0.00242	CcSEcCtD
Sparfloxacin—Dyspnoea—Cisplatin—esophageal cancer	0.000182	0.0024	CcSEcCtD
Sparfloxacin—Flatulence—Capecitabine—esophageal cancer	0.000182	0.0024	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—AJUBA—esophageal cancer	0.000181	0.00688	CbGpPWpGaD
Sparfloxacin—Dysgeusia—Capecitabine—esophageal cancer	0.000181	0.00238	CcSEcCtD
Sparfloxacin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00018	0.00237	CcSEcCtD
Sparfloxacin—Back pain—Capecitabine—esophageal cancer	0.000178	0.00235	CcSEcCtD
Sparfloxacin—Decreased appetite—Cisplatin—esophageal cancer	0.000178	0.00234	CcSEcCtD
Sparfloxacin—Pneumonia—Methotrexate—esophageal cancer	0.000177	0.00233	CcSEcCtD
Sparfloxacin—Pain—Cisplatin—esophageal cancer	0.000175	0.0023	CcSEcCtD
Sparfloxacin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000174	0.0023	CcSEcCtD
Sparfloxacin—Tremor—Capecitabine—esophageal cancer	0.000173	0.00228	CcSEcCtD
Sparfloxacin—Stomatitis—Methotrexate—esophageal cancer	0.000171	0.00226	CcSEcCtD
Sparfloxacin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000171	0.00226	CcSEcCtD
Sparfloxacin—Conjunctivitis—Methotrexate—esophageal cancer	0.000171	0.00225	CcSEcCtD
Sparfloxacin—Sweating—Methotrexate—esophageal cancer	0.000169	0.00222	CcSEcCtD
Sparfloxacin—Feeling abnormal—Cisplatin—esophageal cancer	0.000168	0.00222	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.000168	0.00639	CbGpPWpGaD
Sparfloxacin—Haematuria—Methotrexate—esophageal cancer	0.000168	0.00221	CcSEcCtD
Sparfloxacin—Malaise—Capecitabine—esophageal cancer	0.000166	0.00219	CcSEcCtD
Sparfloxacin—Epistaxis—Methotrexate—esophageal cancer	0.000166	0.00219	CcSEcCtD
Sparfloxacin—Vertigo—Capecitabine—esophageal cancer	0.000166	0.00219	CcSEcCtD
Sparfloxacin—Agranulocytosis—Methotrexate—esophageal cancer	0.000164	0.00216	CcSEcCtD
Sparfloxacin—TOP2A—Cell Cycle—MLH3—esophageal cancer	0.000164	0.00622	CbGpPWpGaD
Sparfloxacin—Palpitations—Capecitabine—esophageal cancer	0.000163	0.00215	CcSEcCtD
Sparfloxacin—Body temperature increased—Cisplatin—esophageal cancer	0.000161	0.00213	CcSEcCtD
Sparfloxacin—Cough—Capecitabine—esophageal cancer	0.000161	0.00212	CcSEcCtD
Sparfloxacin—Hypertension—Capecitabine—esophageal cancer	0.000159	0.0021	CcSEcCtD
Sparfloxacin—Haemoglobin—Methotrexate—esophageal cancer	0.000159	0.00209	CcSEcCtD
Sparfloxacin—Hepatitis—Methotrexate—esophageal cancer	0.000158	0.00208	CcSEcCtD
Sparfloxacin—Haemorrhage—Methotrexate—esophageal cancer	0.000158	0.00208	CcSEcCtD
Sparfloxacin—Myalgia—Capecitabine—esophageal cancer	0.000157	0.00207	CcSEcCtD
Sparfloxacin—Chest pain—Capecitabine—esophageal cancer	0.000157	0.00207	CcSEcCtD
Sparfloxacin—Arthralgia—Capecitabine—esophageal cancer	0.000157	0.00207	CcSEcCtD
Sparfloxacin—Pharyngitis—Methotrexate—esophageal cancer	0.000157	0.00206	CcSEcCtD
Sparfloxacin—Anxiety—Capecitabine—esophageal cancer	0.000157	0.00206	CcSEcCtD
Sparfloxacin—Discomfort—Capecitabine—esophageal cancer	0.000155	0.00205	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000155	0.00588	CbGpPWpGaD
Sparfloxacin—TOP2A—Gastric Cancer Network 2—TP53—esophageal cancer	0.000154	0.00586	CbGpPWpGaD
Sparfloxacin—Dry mouth—Capecitabine—esophageal cancer	0.000154	0.00203	CcSEcCtD
Sparfloxacin—Confusional state—Capecitabine—esophageal cancer	0.000152	0.002	CcSEcCtD
Sparfloxacin—Hypersensitivity—Cisplatin—esophageal cancer	0.000151	0.00198	CcSEcCtD
Sparfloxacin—Erythema multiforme—Methotrexate—esophageal cancer	0.000149	0.00197	CcSEcCtD
Sparfloxacin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000147	0.00194	CcSEcCtD
Sparfloxacin—Tinnitus—Methotrexate—esophageal cancer	0.000147	0.00194	CcSEcCtD
Sparfloxacin—Tachycardia—Capecitabine—esophageal cancer	0.000147	0.00194	CcSEcCtD
Sparfloxacin—Asthenia—Cisplatin—esophageal cancer	0.000147	0.00193	CcSEcCtD
Sparfloxacin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000146	0.00192	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000145	0.00549	CbGpPWpGaD
Sparfloxacin—Anorexia—Capecitabine—esophageal cancer	0.000144	0.00189	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000142	0.00538	CbGpPWpGaD
Sparfloxacin—Chills—Methotrexate—esophageal cancer	0.000142	0.00187	CcSEcCtD
Sparfloxacin—TOP2A—Circadian rythm related genes—GHRL—esophageal cancer	0.000141	0.00535	CbGpPWpGaD
Sparfloxacin—Diarrhoea—Cisplatin—esophageal cancer	0.00014	0.00184	CcSEcCtD
Sparfloxacin—Alopecia—Methotrexate—esophageal cancer	0.000139	0.00184	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.000138	0.00524	CbGpPWpGaD
Sparfloxacin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000137	0.00181	CcSEcCtD
Sparfloxacin—Insomnia—Capecitabine—esophageal cancer	0.000136	0.0018	CcSEcCtD
Sparfloxacin—Paraesthesia—Capecitabine—esophageal cancer	0.000135	0.00178	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000135	0.00511	CbGpPWpGaD
Sparfloxacin—Dysgeusia—Methotrexate—esophageal cancer	0.000135	0.00177	CcSEcCtD
Sparfloxacin—Dyspnoea—Capecitabine—esophageal cancer	0.000134	0.00177	CcSEcCtD
Sparfloxacin—Back pain—Methotrexate—esophageal cancer	0.000133	0.00175	CcSEcCtD
Sparfloxacin—Dyspepsia—Capecitabine—esophageal cancer	0.000133	0.00175	CcSEcCtD
Sparfloxacin—Decreased appetite—Capecitabine—esophageal cancer	0.000131	0.00173	CcSEcCtD
Sparfloxacin—Vomiting—Cisplatin—esophageal cancer	0.00013	0.00171	CcSEcCtD
Sparfloxacin—Rash—Cisplatin—esophageal cancer	0.000129	0.0017	CcSEcCtD
Sparfloxacin—Pain—Capecitabine—esophageal cancer	0.000129	0.0017	CcSEcCtD
Sparfloxacin—Constipation—Capecitabine—esophageal cancer	0.000129	0.0017	CcSEcCtD
Sparfloxacin—Dermatitis—Cisplatin—esophageal cancer	0.000129	0.0017	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000128	0.00487	CbGpPWpGaD
Sparfloxacin—Ill-defined disorder—Methotrexate—esophageal cancer	0.000127	0.00168	CcSEcCtD
Sparfloxacin—Feeling abnormal—Capecitabine—esophageal cancer	0.000124	0.00164	CcSEcCtD
Sparfloxacin—Malaise—Methotrexate—esophageal cancer	0.000124	0.00163	CcSEcCtD
Sparfloxacin—Vertigo—Methotrexate—esophageal cancer	0.000123	0.00163	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000123	0.00162	CcSEcCtD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000122	0.00462	CbGpPWpGaD
Sparfloxacin—Nausea—Cisplatin—esophageal cancer	0.000121	0.0016	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000121	0.00458	CbGpPWpGaD
Sparfloxacin—Cough—Methotrexate—esophageal cancer	0.00012	0.00158	CcSEcCtD
Sparfloxacin—Urticaria—Capecitabine—esophageal cancer	0.00012	0.00158	CcSEcCtD
Sparfloxacin—Abdominal pain—Capecitabine—esophageal cancer	0.000119	0.00157	CcSEcCtD
Sparfloxacin—Body temperature increased—Capecitabine—esophageal cancer	0.000119	0.00157	CcSEcCtD
Sparfloxacin—Convulsion—Methotrexate—esophageal cancer	0.000119	0.00157	CcSEcCtD
Sparfloxacin—Chest pain—Methotrexate—esophageal cancer	0.000117	0.00154	CcSEcCtD
Sparfloxacin—Arthralgia—Methotrexate—esophageal cancer	0.000117	0.00154	CcSEcCtD
Sparfloxacin—Myalgia—Methotrexate—esophageal cancer	0.000117	0.00154	CcSEcCtD
Sparfloxacin—Discomfort—Methotrexate—esophageal cancer	0.000116	0.00152	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000114	0.00434	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000114	0.00433	CbGpPWpGaD
Sparfloxacin—Confusional state—Methotrexate—esophageal cancer	0.000113	0.00149	CcSEcCtD
Sparfloxacin—Anaphylactic shock—Methotrexate—esophageal cancer	0.000112	0.00148	CcSEcCtD
Sparfloxacin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.000112	0.00424	CbGpPWpGaD
Sparfloxacin—Hypersensitivity—Capecitabine—esophageal cancer	0.000111	0.00146	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000111	0.0042	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000111	0.0042	CbGpPWpGaD
Sparfloxacin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00011	0.00145	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000109	0.00414	CbGpPWpGaD
Sparfloxacin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000108	0.00143	CcSEcCtD
Sparfloxacin—Asthenia—Capecitabine—esophageal cancer	0.000108	0.00142	CcSEcCtD
Sparfloxacin—Anorexia—Methotrexate—esophageal cancer	0.000107	0.00141	CcSEcCtD
Sparfloxacin—Pruritus—Capecitabine—esophageal cancer	0.000107	0.0014	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000105	0.00397	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000105	0.00397	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000105	0.00397	CbGpPWpGaD
Sparfloxacin—Diarrhoea—Capecitabine—esophageal cancer	0.000103	0.00136	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.000103	0.00389	CbGpPWpGaD
Sparfloxacin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000102	0.00135	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	0.000101	0.00385	CbGpPWpGaD
Sparfloxacin—Insomnia—Methotrexate—esophageal cancer	0.000101	0.00134	CcSEcCtD
Sparfloxacin—Paraesthesia—Methotrexate—esophageal cancer	0.000101	0.00133	CcSEcCtD
Sparfloxacin—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	0.0001	0.0038	CbGpPWpGaD
Sparfloxacin—Dyspnoea—Methotrexate—esophageal cancer	9.99e-05	0.00132	CcSEcCtD
Sparfloxacin—Somnolence—Methotrexate—esophageal cancer	9.97e-05	0.00131	CcSEcCtD
Sparfloxacin—Dizziness—Capecitabine—esophageal cancer	9.96e-05	0.00131	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	9.93e-05	0.00377	CbGpPWpGaD
Sparfloxacin—Dyspepsia—Methotrexate—esophageal cancer	9.87e-05	0.0013	CcSEcCtD
Sparfloxacin—Decreased appetite—Methotrexate—esophageal cancer	9.74e-05	0.00128	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—esophageal cancer	9.73e-05	0.00369	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	9.72e-05	0.00369	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	9.67e-05	0.00367	CbGpPWpGaD
Sparfloxacin—Pain—Methotrexate—esophageal cancer	9.59e-05	0.00126	CcSEcCtD
Sparfloxacin—Vomiting—Capecitabine—esophageal cancer	9.57e-05	0.00126	CcSEcCtD
Sparfloxacin—Rash—Capecitabine—esophageal cancer	9.49e-05	0.00125	CcSEcCtD
Sparfloxacin—Dermatitis—Capecitabine—esophageal cancer	9.49e-05	0.00125	CcSEcCtD
Sparfloxacin—Headache—Capecitabine—esophageal cancer	9.43e-05	0.00124	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	9.39e-05	0.00356	CbGpPWpGaD
Sparfloxacin—Feeling abnormal—Methotrexate—esophageal cancer	9.24e-05	0.00122	CcSEcCtD
Sparfloxacin—Gastrointestinal pain—Methotrexate—esophageal cancer	9.17e-05	0.00121	CcSEcCtD
Sparfloxacin—Nausea—Capecitabine—esophageal cancer	8.94e-05	0.00118	CcSEcCtD
Sparfloxacin—Urticaria—Methotrexate—esophageal cancer	8.91e-05	0.00117	CcSEcCtD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	8.88e-05	0.00337	CbGpPWpGaD
Sparfloxacin—Abdominal pain—Methotrexate—esophageal cancer	8.86e-05	0.00117	CcSEcCtD
Sparfloxacin—Body temperature increased—Methotrexate—esophageal cancer	8.86e-05	0.00117	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	8.82e-05	0.00335	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—HIST1H2BM—esophageal cancer	8.69e-05	0.0033	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	8.58e-05	0.00326	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	8.55e-05	0.00324	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	8.53e-05	0.00323	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	8.37e-05	0.00317	CbGpPWpGaD
Sparfloxacin—Hypersensitivity—Methotrexate—esophageal cancer	8.26e-05	0.00109	CcSEcCtD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	8.23e-05	0.00312	CbGpPWpGaD
Sparfloxacin—Asthenia—Methotrexate—esophageal cancer	8.04e-05	0.00106	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	7.98e-05	0.00303	CbGpPWpGaD
Sparfloxacin—Pruritus—Methotrexate—esophageal cancer	7.93e-05	0.00105	CcSEcCtD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.93e-05	0.00301	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—NOS2—esophageal cancer	7.91e-05	0.003	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—MAD2L1—esophageal cancer	7.67e-05	0.00291	CbGpPWpGaD
Sparfloxacin—Diarrhoea—Methotrexate—esophageal cancer	7.67e-05	0.00101	CcSEcCtD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	7.65e-05	0.0029	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	7.65e-05	0.0029	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—PSME1—esophageal cancer	7.54e-05	0.00286	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—PSME2—esophageal cancer	7.54e-05	0.00286	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	7.51e-05	0.00285	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	7.43e-05	0.00282	CbGpPWpGaD
Sparfloxacin—Dizziness—Methotrexate—esophageal cancer	7.41e-05	0.000977	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	7.4e-05	0.00281	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—esophageal cancer	7.22e-05	0.00274	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.2e-05	0.00273	CbGpPWpGaD
Sparfloxacin—Vomiting—Methotrexate—esophageal cancer	7.13e-05	0.00094	CcSEcCtD
Sparfloxacin—Rash—Methotrexate—esophageal cancer	7.07e-05	0.000932	CcSEcCtD
Sparfloxacin—Dermatitis—Methotrexate—esophageal cancer	7.06e-05	0.000931	CcSEcCtD
Sparfloxacin—Headache—Methotrexate—esophageal cancer	7.02e-05	0.000926	CcSEcCtD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	6.99e-05	0.00265	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	6.98e-05	0.00265	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—BUB1B—esophageal cancer	6.86e-05	0.0026	CbGpPWpGaD
Sparfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	6.76e-05	0.00257	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—PSME1—esophageal cancer	6.74e-05	0.00256	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—PSME2—esophageal cancer	6.74e-05	0.00256	CbGpPWpGaD
Sparfloxacin—Nausea—Methotrexate—esophageal cancer	6.66e-05	0.000878	CcSEcCtD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	6.38e-05	0.00242	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	6.35e-05	0.00241	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	6.19e-05	0.00235	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—BUB1B—esophageal cancer	6.14e-05	0.00233	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	6.06e-05	0.0023	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CHEK2—esophageal cancer	5.84e-05	0.00221	CbGpPWpGaD
Sparfloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—esophageal cancer	5.79e-05	0.0022	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	5.7e-05	0.00216	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.47e-05	0.00208	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	5.29e-05	0.00201	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	5.26e-05	0.002	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	5.1e-05	0.00194	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.04e-05	0.00191	CbGpPWpGaD
Sparfloxacin—ABCB1—Allograft Rejection—CASP8—esophageal cancer	4.96e-05	0.00188	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—EP300—esophageal cancer	4.84e-05	0.00183	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	4.67e-05	0.00177	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	4.44e-05	0.00168	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	4.41e-05	0.00167	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.39e-05	0.00167	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.38e-05	0.00166	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.29e-05	0.00163	CbGpPWpGaD
Sparfloxacin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	4.29e-05	0.00163	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.21e-05	0.0016	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	4.15e-05	0.00157	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	3.93e-05	0.00149	CbGpPWpGaD
Sparfloxacin—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	3.88e-05	0.00147	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	3.76e-05	0.00143	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	3.75e-05	0.00142	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.73e-05	0.00141	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	3.64e-05	0.00138	CbGpPWpGaD
Sparfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.6e-05	0.00137	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	3.6e-05	0.00136	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	3.6e-05	0.00136	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—RB1—esophageal cancer	3.57e-05	0.00135	CbGpPWpGaD
Sparfloxacin—TOP2A—Circadian rythm related genes—TP53—esophageal cancer	3.46e-05	0.00131	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	3.45e-05	0.00131	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.21e-05	0.00122	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—RB1—esophageal cancer	3.19e-05	0.00121	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	3.14e-05	0.00119	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.08e-05	0.00117	CbGpPWpGaD
Sparfloxacin—SLC22A5—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.81e-05	0.00107	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CDKN2A—esophageal cancer	2.8e-05	0.00106	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.73e-05	0.00103	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—esophageal cancer	2.65e-05	0.001	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	2.56e-05	0.000972	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	2.47e-05	0.000939	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	2.45e-05	0.000928	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—EP300—esophageal cancer	2.44e-05	0.000925	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	2.44e-05	0.000924	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—SLC52A3—esophageal cancer	2.43e-05	0.000922	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—BLVRB—esophageal cancer	2.43e-05	0.000922	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CCND1—esophageal cancer	2.37e-05	0.000899	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—CDKN1A—esophageal cancer	2.29e-05	0.000869	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—EP300—esophageal cancer	2.18e-05	0.000827	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle, Mitotic—MYC—esophageal cancer	2.12e-05	0.000806	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.1e-05	0.000796	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CA1—esophageal cancer	2.07e-05	0.000784	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.07e-05	0.000784	CbGpPWpGaD
Sparfloxacin—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.06e-05	0.00078	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.04e-05	0.000774	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.99e-05	0.000757	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—MYC—esophageal cancer	1.9e-05	0.000721	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CA2—esophageal cancer	1.89e-05	0.000717	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.8e-05	0.000684	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ADH7—esophageal cancer	1.76e-05	0.000667	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PLCE1—esophageal cancer	1.76e-05	0.000667	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.74e-05	0.000661	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.66e-05	0.000629	CbGpPWpGaD
Sparfloxacin—TOP2A—Cell Cycle—TP53—esophageal cancer	1.56e-05	0.000592	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ADH1B—esophageal cancer	1.54e-05	0.000585	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.51e-05	0.000572	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—TYMP—esophageal cancer	1.47e-05	0.000559	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.45e-05	0.000548	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.43e-05	0.000544	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.41e-05	0.000536	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ALOX15—esophageal cancer	1.4e-05	0.00053	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—TPI1—esophageal cancer	1.33e-05	0.000505	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTO1—esophageal cancer	1.33e-05	0.000505	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ALDOB—esophageal cancer	1.28e-05	0.000484	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GAPDH—esophageal cancer	1.23e-05	0.000466	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.23e-05	0.000465	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CRABP1—esophageal cancer	1.22e-05	0.000462	CbGpPWpGaD
Sparfloxacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.19e-05	0.00045	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GNG7—esophageal cancer	1.16e-05	0.00044	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ALDH2—esophageal cancer	1.09e-05	0.000412	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—GSTT1—esophageal cancer	1.03e-05	0.000392	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.02e-05	0.000387	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—ENO1—esophageal cancer	9.68e-06	0.000367	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PTGS1—esophageal cancer	9.68e-06	0.000367	CbGpPWpGaD
Sparfloxacin—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.67e-06	0.000367	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PSME1—esophageal cancer	9.54e-06	0.000362	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PSME2—esophageal cancer	9.54e-06	0.000362	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CYP1B1—esophageal cancer	8.23e-06	0.000312	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.74e-06	0.000293	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—HMOX1—esophageal cancer	7.06e-06	0.000268	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—CREBBP—esophageal cancer	4.53e-06	0.000172	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—NOS3—esophageal cancer	4.05e-06	0.000154	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PTGS2—esophageal cancer	3.71e-06	0.000141	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—EP300—esophageal cancer	3.08e-06	0.000117	CbGpPWpGaD
Sparfloxacin—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.28e-06	8.66e-05	CbGpPWpGaD
